Digest Network Come funziona
Network
/
Società
Gi
Non verificato

Gilead Sciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

88 comunicati stampa

Guarda tutti i comunicati
24/11/2025
Associazioni/Professionisti
Salute
Sanità
Fitness
Farmaceutica
Biotecnologia
Industria
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
18/11/2025
Mercato del lavoro
Industria
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Farmaceutica
Biotecnologia
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
13/11/2025
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
07/11/2025
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Gilead Provides Update on Phase 3 ASCENT-07 Study
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
07/11/2025
Igiene alimentare
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Eventi
Web e Social Network
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Gilead Sciences to Present at Upcoming Investor Conferences
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Multimedialità
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Medicina - Varie
Eventi
Fiere
Industria
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
31/10/2025
Eventi
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Farmaceutica
Biotecnologia
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Oncologia
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Gilead Sciences Announces Third Quarter 2025 Financial Results
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
23/10/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Eventi
Industria
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0